Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
18 Julho 2023 - 6:00PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
therapies for rare and ultra-rare diseases, today reported the
grant of 36,300 restricted stock units of the company’s common
stock to 21 newly hired non-executive officers of the company. The
awards were approved by the compensation committee of the company’s
board of directors and granted under the Ultragenyx Employment
Inducement Plan, with a grant date of July 16, 2023, as an
inducement material to the new employees entering into employment
with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years,
with 25% of the underlying shares vesting on each anniversary of
the grant date, subject to the employee being continuously employed
by the company as of such vesting dates.
About Ultragenyx Pharmaceutical
Inc.Ultragenyx is a biopharmaceutical company committed to
bringing novel products to patients for the treatment of serious
rare and ultra-rare genetic diseases. The company has built a
diverse portfolio of approved therapies and product candidates
aimed at addressing diseases with high unmet medical need and clear
biology for treatment, for which there are typically no approved
therapies treating the underlying disease.
The company is led by a management team experienced
in the development and commercialization of rare disease
therapeutics. Ultragenyx’s strategy is predicated upon time- and
cost-efficient drug development, with the goal of delivering safe
and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit
the company's website at: www.ultragenyx.com.
Contact Ultragenyx Investors & MediaJoshua
Higa(415) 475-6370
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024